Elucid Announces First Patient Enrollment in AI-PREDICT, a Landmark International Study to Define Lesion-Level Cardiovascular Risk
Elucid, an innovator in AI-powered coronary CT angiography (CCTA) analysis, today announced first patient enrollment in AI-PREDICT, a retrospective, international, multicenter study designed to establish a new lesion-centric paradigm for cardiovascular risk stratification.
Elucid to Showcase CCTA Vision at SCCT 2026, Defining the Future of Personalized Cardiovascular Care
Elucid, an innovator in AI-powered coronary CT angiography (CCTA) analysis, today announced its largest and most comprehensive presence to date at the Society of Cardiovascular Computed Tomography Annual Scientific Meeting (SCCT 2026), taking place July 9 – 12, 2026, at the Gaylord Pacific Resort & Convention Center in Chula Vista, Calif.
Elucid’s Plaque-IQ™ Named “Best New Cardiology Technology Solution” in 2026 MedTech Breakthrough Awards Program
Elucid today announced that its Plaque-IQ arterial plaque analysis software has been selected as winner of the “Best New Cardiology Technology Solution” award in the 10th annual MedTech Breakthrough Awards.
Elucid Announces Commercial Availability of Lesion Inspection Tool for Plaque-IQ™
Elucid announced today the commercial availability of a new Lesion Inspection Tool for coronary and carotid plaque analysis in its novel Plaque-IQ software suite.
Elucid Announces Broad Reimbursement for Quantitative Coronary Plaque Analysis
Effective January 1, 2026, its Plaque-IQ™ coronary plaque analysis has received a new Category I Current Procedural Terminology (CPT®) designation, alongside increasingly widespread coverage and reimbursement from both public and private payors. Together, these developments underscore the clinical value of coronary plaque analysis and establish favorable conditions for broader adoption of the technology.
Elucid Gains Broad CMS Reimbursement of Coronary Plaque Analysis Using PlaqueIQ™
Elucid has announced new Hospital Outpatient Prospective Payment (OPPS) and Physician Fee Schedule (PFS) decisions from the U.S. Centers for Medicare & Medicaid Services (CMS) that establish significant reimbursement for coronary plaque analysis using PlaqueIQ across care settings.
Elucid Launches PlaqueIQ Image Analysis Software for the Carotid Arteries
Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, announced the launch of its PlaqueIQTM image analysis software for the quantification and classification of plaque morphology in the carotid arteries.
Elucid’s PlaqueIQ™ Image Analysis Software Now Covered by United Healthcare
Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, announced that United Healthcare has updated its cardiac imaging guidelines to fully align with recent recommendations from radiology benefit manager EviCore.
Elucid Names Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH Board Directors
Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has made two additions to its Board of Directors. The company named Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH as board directors.
Elucid Applauds CMS Inclusion of Coronary CTA with Plaque Analysis in 2026 Proposed Medicare Physician Fee Schedule
Elucid today released a statement commending U.S. Centers for Medicare & Medicaid Services (CMS) for the inclusion of a Category I CPT code for coronary plaque analysis and a national Medicare average payment amount of over $1,000, pending the final Medicare Physician Fee Schedule (PFS) ruling, which will come out in November.